A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma

Inclusion Criteria: * Adult patients \>/= 21 years of age * Advanced or metastatic and/or unresectable hepatocellular carcinoma * At least 1 measurable lesion according to RECIST criteria * Primary tumor in situ (Expansion Cohort Part I, Part II) * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Adequate bone marrow, liver and renal function Exclusion Criteria: * Prior systemic treatment for metastatic hepatocellular carcinoma or patients who had tumor removed (Expansion Cohort Part I, Part II) * Major surgery within previous 4 weeks or planned major surgical procedure during course of study * Radiation therapy within 28 days prior to start of study treatment * Serious non-healing wound, ulcer ore bone fracture * History of uncontrolled seizures or encephalopathy within the last 6 months * Current central nervous system (CNS) metastases or spinal cord compression * History of gastrointestinal perforation or esophageal/gastric bleeding within 6 months prior to study enrollment * History of another primary malignancy and off treatment for \</= 3 years, except for non-melanoma skin cancer and carcinoma in situ of the cervix * Patients with prior liver transplant * Inadequately controlled hypertension or prior history of hypertensive crisis or hypertensive encephalopathy * Active bleeding diathesis